Comparison of Taqman low density array (TLDA) five-gene assay for tumor cells in bone marrow and blood with histologic bone marrow examination and imaging for disease assessment and outcome in patients with recurrent/refractory neuroblastoma (NBL): A new approaches to neuroblastoma therapy (NANT) study.
Araz Marachelian
No relevant relationships to disclose
Judith Villablanca
No relevant relationships to disclose
Shahab Asgharzadeh
No relevant relationships to disclose
Wei Yao Liu
No relevant relationships to disclose
Betty Liu
No relevant relationships to disclose
Sabrina Young
No relevant relationships to disclose
Brian D. Weiss
No relevant relationships to disclose
Howard M. Katzenstein
No relevant relationships to disclose
Susan Lerner Cohn
Stock Ownership - Abbott Laboratories; Amerigroup; Amgen (I); Amgen; BARD; Biogen Idec; Bristol-Myers Squibb; Catalyst Health Solutions; Express Scripts (I); Gilead Sciences (I); Gilead Sciences; Impax Laboratories; Integra LifeSciences; Jazz Pharmaceuticals; Johnson & Johnson; Kinetic Concepts; LabCorp; Laboratory America; Lilly; Medicis Pharmaceutical; Mednax Inc; Medtronic; Merck; Novartis; PDL Biopharma; Perrigo; Pfizer; Quest Diagnostics; QuestCor; Sanofi (I); Sanofi ; Stryker; SXC Health Solutions; Teva (I); Teva; Thermo Fisher Scientific; United Therapeutic Del Com (I); United Therapeutic Del Com; UnitedHealth Group ; Valeant Pharmaceuticals International; Varian (I); Varian; WellPoint; Zimmer
Sylvain Baruchel
No relevant relationships to disclose
Clare Twist
No relevant relationships to disclose
Meaghan Granger
No relevant relationships to disclose
Katherine K. Matthay
No relevant relationships to disclose
Jemily Malvar
No relevant relationships to disclose
Richard Sposto
No relevant relationships to disclose
Robert Seeger
No relevant relationships to disclose